BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24633422)

  • 21. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 22. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of thyroid cancer driven by known and novel ALK fusions.
    Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
    Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.
    Pérot G; Soubeyran I; Ribeiro A; Bonhomme B; Savagner F; Boutet-Bouzamondo N; Hostein I; Bonichon F; Godbert Y; Chibon F
    PLoS One; 2014; 9(1):e87170. PubMed ID: 24475247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rearranged anaplastic lymphoma kinase (ALK) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors.
    Hamatani K; Mukai M; Takahashi K; Hayashi Y; Nakachi K; Kusunoki Y
    Thyroid; 2012 Nov; 22(11):1153-9. PubMed ID: 23050789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
    Bayliss R; Choi J; Fennell DA; Fry AM; Richards MW
    Cell Mol Life Sci; 2016 Mar; 73(6):1209-24. PubMed ID: 26755435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Unique, Heterozygous Germline Mutation, STK11 (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing Treatment for Neuroblastoma.
    Buryk MA; Picarsic JL; Creary SE; Shaw PH; Simons JP; Deutsch M; Monaco SE; Nikiforov YE; Witchel SF
    Pediatr Dev Pathol; 2015; 18(4):318-23. PubMed ID: 25751324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational analysis of metastatic lymph nodes from papillary thyroid carcinoma in adult and pediatric patients.
    Shifrin AL; Fischer M; Paul T; Erler B; Gheysens K; Baodhankar P; Song-Yang JW; Taylor S; Timmaraju VA; Topilow A; Mireskandari A; Kumar G
    Surgery; 2017 Jan; 161(1):176-187. PubMed ID: 27866718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
    Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
    Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
    Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
    Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
    Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
    Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
    Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A patient with complex multiple genomic ALK alterations.
    Liu X; Rice SJ; Jamis-Dow CA; Abendroth C; Ali S; Almokadem S; Belani CP
    Thorax; 2016 Apr; 71(4):383-5. PubMed ID: 26839360
    [No Abstract]   [Full Text] [Related]  

  • 40. Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy.
    Wang Q; He Y; Yang X; Wang Y; Xiao H
    BMC Pulm Med; 2014 May; 14():83. PubMed ID: 24885608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.